Бекли қоры: Есірткі саясатын реформалау және психоактивтік заттарды зерттеу

UK based think tank and UN accredited NGO

The Beckley Foundation is a UK based think tank and UN accredited NGO, dedicated to activating global drug policy reform and initiating scientific research into psychoactive substances. The foundation is a charitable trust which collaborates with leading scientific and political institutions worldwide to design and develop research and global policy initiatives. It also investigates consciousness and its modulation from a multidisciplinary perspective, working in collaboration with scientists. The foundation is based at Beckley Park near Oxford, United Kingdom. It was founded in 1998, and is directed by Amanda Feilding, Countess of Wemyss.

Since its creation by Amanda Feilding in 1998, the Beckley Foundation has been at the forefront of global drug policy reform and scientific research into psychoactive substances. The Beckley Foundation Scientific Programme initiates, designs and conducts research into the effects of psychoactive substances on the brain, in order to minimise their potential harms, learn more about consciousness and brain function, and discover and explore their therapeutic potential. Recent research includes collaborations with Dr Jordi Riba at Sant Pau Hospital on ayahuasca, Professor David Nutt at Imperial College on the effects of psychedelics on cerebral blood flow, Professor Valerie Curran at University College London on the effects of cannabis on the brain with a view to possible therapeutic applications and with Professor Roland R. Griffiths at Johns Hopkins University studying the effects of psilocybin in
combating addiction. The Beckley Foundation Policy Programme is dedicated to improving national and global drug policies, through research that increases understanding of the health, social and fiscal implications of drug policy, and the development of new evidence based and rational approaches. It brings together country representatives, science and policy experts at international seminars in order to discuss alternative drug policy, and commissions and disseminates reports to open up and facilitate debate among policy makers and the public.

Following the election of Gustavo Petro in August 2022, and in advance of the publication of their full "Cocaine Papers" in late 2022, the Foundation published an in depth review of Colombia's 2020 regulation bill, written by David Restrepo of Centro de Estudios sobre Seguridad y Drogas (CESED). The report provided a qualitative analysis of coca and cocaine regulation, its effects on the supply system, and the associated benefit and cost outcomes for Colombia.

In 2022, the Beckley Foundation joined the Psychedelic Access and Research European Alliance – a collective of charities, patient groups, non profits, and psychedelic industry partners aiming to provide evidence based policy recommendations to the European Union.

The Beckley Foundation Drug Policy Programme was created to promote rational discussion on delicate global arrangement issues. It intended to provide drug strategy advice to academics, substance misuse specialists, strategy developers, and the general public. Senior officials, top researchers, and practitioners evaluated the most recent data on the success of drug policies.

In 2022, the Beckley Foundation joined in the launch of the International Therapeutic Psilocybin Rescheduling Initiative, a global coalition working to promote and secure a rescheduling of psilocybin under the 1971 Convention on Psychotropic Substances. The ITPRI is seeking a worldwide policy change in order to facilitate research into the therapeutic potential of the substance. Partners of the coalition include the Multidisciplinary Association for Psychedelic Studies (MAPS), Mind Medicine Australia, Drug Science and Open Foundation.

To coincide with the introduction of the UK's Psychoactive Substances Act 2016 on 26 May 2016, Amanda Feilding released the report, "Roadmaps to Regulation: New Psychoactive Substances". The document surveys the complex and unique world of NPS production and distribution and suggests a harm reductive model for the legal regulation of this vast array of substances. The NPS report is part of wider family of forthcoming reports, "Roadmaps to Regulation: Cannabis, Psychedelics, MDMA and NPS".

In 2011 an open letter from the Foundation was published in The Times and The Guardian calling for a new approach to drug policy. The letter opened by emphatically stating that the war on drugs has failed and calling for a new approach. Signatories of the letter now include the current Presidents of Colombia (Juan Manuel Santos) and Guatemala (Otto Pérez Molina), and former Presidents of the United States (Jimmy Carter), Mexico, Colombia and Switzerland, as well as Nobel Prize winners and numerous other world figures.

The Global Initiative for Drug Policy Reform is a collaboration between the All Party Parliamentary Group on Drug Policy, the Global Commission on Drug Policy and the Beckley Foundation. It was held at the House of Lords in November 2011, bringing together representatives from countries interested in reform, and countries that have successfully implemented alternative drug policies, along with the Global Commission on Drug Policy.

A preliminary study conducted within the framework of the Beckley Sant Pau Research Programme and in collaboration with the Spanish National Research Council found that harmine and tetrahydroharmine, the alkaloids present in highest amounts in ayahuasca, have potent neurogenic properties (the ability to create new brain cells). The addition of harmine and tetrahydroharmine to cultures containing neural stem cells dramatically increased their differentiation and maturation into neurons.

Based on the Beckley/Imperial Research Programme's psilocybin study brain imaging results, in 2012, the Medical Research Council awarded funding to the programme for a clinical study investigating psilocybin in the treatment of depression. Results from the study, published in the Lancet Psychiatry Journal, showed that two doses of psilocybin lifted depression in all 12 volunteers for three weeks, and kept five of them depression free for three months. The size of the study and the absence of a placebo make the research proof of principle only, but the remarkably positive results highlight the need for continued research in this promising area of psychiatry – psychedelic assisted therapy. Amanda Feilding and the Beckley Foundation are currently trying to secure funding to expand this research and further evaluate the potential of psilocybin as a treatment for depression.

On 13 April 2016, the Beckley/Imperial Research Programme released the world's first images of the human brain on LSD, collected as part of the first ever brain imaging study to examine the effects of LSD on the human brain. Programme co directors Amanda Feilding and David Nutt, together with lead investigator Robin Carhart Harris, held a press conference at the Royal Society on 11 April 2016 to herald the publication of the paper.

Two separate Beckley Foundation collaborative projects, at Imperial College London and Maastricht University, are carrying out research into the effects of low doses of LSD, also known as microdoses, in humans, in order to investigate its pharmacology and potential benefits for health and wellbeing. The Maastricht project focuses in particular on mood, cognitive functions, and pain management, and has produced evidence for some benefits to microdosing on cognitive function and pain tolerance. At Imperial College, researchers collaborated with the Beckley Foundation on the development of an innovative, naturalistic study design in order to investigate the practice of microdosing in 'real life', with a sizeable number of subjects, and for a fraction of the cost of a lab based study. It represented the first ever psychedelic study to use placebo control outside of the lab, and was completed by 191 participants, making it by far the largest placebo controlled psychedelic study to date.

News reports in 2018 2019 indicated that the Foundation had been retained by the Canadian cannabis producer Canopy Growth Corporation to conduct research as to the benefits of various strains of its products, particularly in treating pain, anxiety and drug addiction. One goal is to reduce dependence on opioids in treating cancer related pain. The two formed Beckley Canopy Therapeutics in Oxford, to raise funds from investors for cannabinoid research and drug development. Canopy Growth has been planning to export its products to the UK. The long term intent of the partnership is to confirm the value of cannabis in specific conditions and to convince insurers to pay for medical cannabis when used accordingly. Mark Ware, Canopy's chief medical officer, said in an interview that Feilding's "ability to take a scientific look at what would otherwise be considered as controversial therapeutics makes her a very good partner". Feilding's son, Cosmo Feilding Mellen, is the managing director of the partnership.

The Beckley/Maastricht Microdosing Research Programme at Maastricht University in the Netherlands, carrying out research into the effects of LSD microdosing on humans, with a particular focus on mood, cognitive functions, and pain management. The first study, exploring the dose response relationship in LSD induced physiological and psychological effects, saw twenty four healthy volunteers each receive single doses of 5, 10 and 20 micrograms of LSD, or a placebo.

The Beckley Foundation/Imperial College London Psychedelic Research Programme, investigating the effects of psilocybin and other psychedelic drugs on cerebral blood flow, and linking this with cognitive effects (for example, improved episodic memory recall and increased vividness of subjective experience under the influence of psilocybin). The Beckley Foundation Ethnobotanical Research Programme, investigating the effects and potential benefits of Ayahuasca and DMT, including a study involving ketanserin on evaluating the effects of glutamate release by DMT, a study investigating the association between brain plasticity and Ayahuasca, and a long term study investigating the effect of Ayahuasca on personal development and health. A Beckley Foundation/Johns Hopkins University collaboration investigating the potential use of psychedelic drugs to treat addiction. A pilot study using psilocybin to treat nicotine addiction produced promising results, leading to a multi site clinical trial in the USA, funded by NIH, in which the Foundation is not involved. A Beckley Foundation/King's College London collaboration with Dr Paul Morrison at the Institute of Psychiatry investigating the differing effects of delta 9 tetrahydrocannabinol (THC) and cannabidiol (CBD), two of the main cannabinoids found in cannabis that determine its subjective and cognitive effects. Cannabidiol is showing promise in inhibiting the psychosis like effects of THC, and indicating great therapeutic potential. A Beckley Foundation/University College London collaboration with Professor Valerie Curran investigating medicinal uses of cannabis. A Beckley/Imperial Psychedelic Research Programme collaborative study on psychedelic microdosing.